Johnson & Johnson’s problems over its antipsychotic drug Risperdal continue. On April 11 a Little Rock state court judge ordered the company to pay the state of Arkansas $1.2 billion. The order followed a jury verdict against J&J that found that Johnson & Johnson and subsidiary Janssen Pharmaceuticals Inc. had defrauded the state’s Medicaid program when it hid the risks associated with Risperdal.
J&J’s lead lawyer was Thomas Campion of Drinker Biddle & Reath; the company has already announced an intention to appeal.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
